The histone deacetylase inhibitor valproic acid enhances equine herpesvirus type 1 (EHV-1)-mediated oncolysis of human glioma cells

Cancer Gene Therapy

Volumn 20, Issue 2, 2013, Pages 88-93

  White, M C ^a   Frampton, A R ^a  

^a UNIVERSITY OF NORTH CAROLINA WILMINGTON   (United States)

Author keywords

EHV 1; glioblastoma; valproic acid; virotherapy

Indexed keywords

HISTONE DEACETYLASE INHIBITOR; VALPROIC ACID;

ANIMAL VIRUS; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL DIVISION; CELL SPREADING; CONTROLLED STUDY; CYTOLYSIS; DRUG EFFECT; GLIOBLASTOMA; GLIOMA CELL; HERPES SIMPLEX VIRUS 1; HERPES VIRUS INFECTION; HORSE; HUMAN; HUMAN CELL; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; VIRUS ENTRY; VIRUS REPLICATION;

ANIMALS; BRAIN NEOPLASMS; GENETIC VECTORS; GLIOMA; HERPESVIRUS 1, EQUID; HISTONE DEACETYLASE INHIBITORS; HORSES; HUMANS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; VALPROIC ACID;

ANIMALIA; EQUID HERPESVIRUS 1;

EID: 84874112666     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2012.89     Document Type: Article

References (42)

1. Lim SK, Llaguno SRA, McKay RM, Parada LF. Glioblastoma multiforme: a perspective on recent findings in human cancer and mouse models. BMB Rep, 2011; 44: 158-164.
2. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med 2008; 359: 492-507.
3. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-996.
4. Grossman SA, Ye X, Piantadosi S, Desideri S, Nabors LB, Rosenfeld M et al. Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States. Clin Cancer Res 2010; 16: 2443-2449.
5. Maher EA, Furnari FB, Bachoo RM, Rowitch DH, Louis DN, Cavenee WK et al. Malignant glioma: genetics and biology of a grave matter. Genes Dev 2001; 15: 1311-1333.
6. Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 2001; 95: 190-198.
7. Kambara H, Okano H, Chiocca EA, Saeki Y. An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor. Cancer Res 2005; 65: 2832-2839.
8. Bieler A, Mantwill K, Dravits T, Bernshausen A, Glockzin G, Kohler-Vargas N et al. Novel three-pronged strategy to enhance cancer cell killing in glioblastoma cell lines: histone deacetylase inhibitor, chemotherapy, and oncolytic adenovirus dl520. Hum Gene Ther 2006; 17: 55-70.
9. Lun X, Senger DL, Alain T, Oprea A, Parato K, Stojdl D et al. Effects of intravenously administered recombinant vesicular stomatitis virus (VSVDM51) on multifocal and invasive gliomas. J Natl Cancer Inst 2006; 98: 1546-1557.
10. Freeman AI, Zakay-Rones Z, Gomori JM, Linetsky E, Rasooly L, Greenbaum E et al. Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme. Mol Ther 2006; 13: 221-228.
11. Lun X, Yang W, Alain T, Shi ZQ, Muzik H, Barrett JW et al. Myxoma virus is a novel oncolytic virus with significant antitumor activity against experimental human gliomas. Cancer Res 2005; 65: 9982-9990.
12. Lun XQ, Jang J-H, Tang N, Deng H, Head R, Bell JC et al. Efficacy of systemically administered oncolytic vaccinia virotherapy for malignant gliomas is enhanced by combination therapy with rapamycin or cyclophosphamide. Clin Cancer Res 2009; 15: 2777-2788.
13. Courchesne MJ, White MC, Stanfield BA, Frampton AR. Equine Herpesvirus type 1-mediated oncolysis of human glioblastoma multiforme cells. J Virol 2012; 86: 2882-2886.
14. Davison AJ, Wilkie NM. Location and orientation of homologous sequences in the genomes of five herpesviruses. J Gen Virol 1983; 64: 1927-1942.
15. Telford EA, Watson MS, McBride K, Davison AJ. The DNA sequence of equine herpesvirus-1. Virology 1992; 189: 304-316.
16. Reed SM, Toribio RE. Equine herpesvirus 1 and 4. Vet Clin North Am Equine Pract 2004; 20: 631-642.
17. Trapp S, von Einem J, Hofmann H, Kö stler J, Wild J, Wagner R et al. Potential of equine herpesvirus 1 as a vector for immunization. J Virol 2005; 79: 5445-5454.
18. Van Lint C, Emiliani S, Verdin E. The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. Gene Expr 1996; 5: 245-253.
19. Okada T, Uchibori R, Iwata-Okada M, Takahashi M, Nomoto T, Nonaka-Sarukawa M et al. A histone deacetylase inhibitor enhances recombinant adeno-associated virus-mediated gene expression in tumor cells. Mol Ther 2006; 13: 738-746.
20. MacTavish H, Diallo J-S, Huang B, Stanford M, Le Boeuf F, De Silva N et al. Enhancement of vaccinia virus based oncolysis with histone deacetylase inhibitors. PLoS One 2010; 5: e14462.
21. Liu T-C, Castelo-Branco P, Rabkin SD, Martuza RL, Trichostatin A, Oncolytic HSV. Combination therapy shows enhanced antitumoral and antiangiogenic effects. Mol Ther 2008; 16: 1041-1047.
22. Segura-Pacheco B, Avalos B, Rangel E, Velazquez D, Cabrera G. HDAC inhibitor valproic acid upregulates CAR in vitro and in vivo. Genet Vaccines Ther 2007; 5: 10.
23. Magner WJ, Kazim AL, Stewart C, Romano MA, Catalano G, Grande C et al. Activation of MHC class I, II, and CD40 gene expression by histone deacetylase inhibitors. J Immunol 2000; 165: 7017-7024.
24. Kitazono M, Goldsmith ME, Aikou T, Bates S, Fojo T. Enhanced adenovirus transgene expression in malignant cells treated with the histone deacetylase inhibitor FR901228. Cancer Res 2001; 61: 6328-6330.
25. Otsuki A, Patel A, Kasai K, Suzuki M, Kurozumi K, Chiocca EA et al. Histone deacetylase inhibitors augment antitumor efficacy of herpes-based oncolytic viruses. Mol Ther 2008; 16: 1546-1555.
26. Alvarez-Breckenridge CA, Yu J, Price R, Wei M, Wang Y, Nowicki MO et al. The HDAC inhibitor valproic acid lessens NK cell action against oncolytic virus-infected glioblastoma cells with inhibition of STAT5/T-BET signaling and IFNg generation. J Virol 2012; 86: 4566-4577.
27. Vlasáková J, Nováková Z, Rossmeislová L, Kahle M, Hozák P, Hodny Z. Histone deacetylase inhibitors suppress IFNa-induced up-regulation of promyelocytic leukemia protein. Blood 2007; 109: 1373-1380.
28. Frampton Jr AR, Smith PM, Zhang Y, Matsumura T, Osterrieder N, O'Callaghan DJ. Contribution of gene products encoded within the unique short segment of equine herpesvirus 1 to virulence in a murine model. Virus Res 2002; 90: 287-301.
29. Niyazi M, Siefert A, Schwarz SB, Ganswindt U, Kreth F-W, Tonn J-C et al. Therapeutic options for recurrent malignant glioma. Radiother Oncol 2011; 98: 1-14.
30. Fu X, Tao L, Rivera A, Zhang X. Rapamycin enhances the activity of oncolytic herpes simplex virus against tumor cells that are resistant to virus replication. Int J Cancer 2011; 129: 1503-1510.
31. Nguyen TL-A, Wilson MG, Hiscott J. Oncolytic viruses and histone deacetylase inhibitors-a multi-pronged strategy to target tumor cells. Cytokine Growth Factor Rev 2010; 21: 153-159.
32. Ottolino-Perry K, Diallo J-S, Lichty BD, Bell JC, Andrea McCart J. Intelligent design: combination therapy with oncolytic viruses. Mol Ther 2009; 18: 251-263.
33. Khan A, Gregorie C, Tomasi T. Histone deacetylase inhibitors induce TAP, LMP, Tapasin genes and MHC class I antigen presentation by melanoma cells. Cancer Immunol Immunother 2008; 57: 647-654.
34. Chang H-M, Paulson M, Holko M, Rice CM, Williams BRG, Marié I et al. Induction of interferon-stimulated gene expression and antiviral responses require protein deacetylase activity. Proc Nat Acad Sci USA 2004; 101: 9578-9583.
35. Suh H-S, Choi S, Khattar P, Choi N, Lee S. Histone deacetylase inhibitors suppress the expression of inflammatory and innate immune response genes in human microglia and astrocytes. J Neuroimmune Pharm 2010; 5: 521-532.
36. Fulci G, Breymann L, Gianni D, Kurozomi K, Rhee SS, Yu J et al. Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses. Proc Natl Acad Sci USA 2006; 103: 12873-12878.
37. Osuka S, Takano S, Watanabe S, Ishikawa E, Yamamoto T, Matsumura A. Valproic acid inhibits angiogenesis in vitro and glioma angiogenesis in vivo in the brain. Neurol Med Chir 2012; 52: 186-193.
38. Wagner B, Wimer C, Freer H, Osterrieder N, Erb HN. Infection of peripheral blood mononuclear cells with neuropathogenic equine herpesvirus type-1 strain Ab4 reveals intact interferon-a induction and induces suppression of anti-inflammatory interleukin-10 responses in comparison to other viral strains. Vet Immunol Immunopathol 2011; 143: 116-124.
39. Even DL, Henley AM, Geraghty RJ. The requirements for herpes simplex virus type 1 cell-cell spread via nectin-1 parallel those for virus entry. Virus Res 2006; 119: 195-207.
40. Tiwari V, Oh MJ, Kovacs M, Shukla SY, Valyi-Nagy T, Shukla D. Role for nectin-1 in herpes simplex virus 1 entry and spread in human retinal pigment epithelial cells. FEBS J 2008; 275: 5272-5285.
41. Yamamoto M, Curiel DT. Current issues and future directions of oncolytic adenoviruses. Mol Ther 2009; 18: 243-250.
42. Kaur B, Chiocca EA, Cripe TP. Oncolytic HSV-1 virotherapy: clinical experience and opportunities for progress. Curr Pharm Biotechnol 2012; 13: 1842-1851.